^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Case Report: A patient with the rare third-generation TKI-resistant mutation EGFR L718Q who responded to afatinib plus cetuximab combination therapy

Published date:
10/31/2022
Excerpt:
...we demonstrated the first use of combination therapy with afatinib and cetuximab for a patient with an L858R/L718Q mutation who achieved a response after almonertinib resistance.
DOI:
https://doi.org/10.3389/fonc.2022.995624